PMID- 29879039
OWN - NLM
STAT- MEDLINE
DCOM- 20180613
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 23
DP  - 2018 Jun
TI  - A retrospective study of Ganoderma Lucidum Spore Powder for patients with 
      epilepsy.
PG  - e10941
LID - 10.1097/MD.0000000000010941 [doi]
LID - e10941
AB  - This study firstly investigated the feasibility effect and safety of Ganoderma 
      Lucidum Spore Powder (GLSP) for treating patients with epilepsy.Eighteen eligible 
      patients with epilepsy were included. They all received GLSP treatment for a 
      total of 8 weeks. The primary outcome included weekly seizure frequency. The 
      secondary outcomes consisted of each seizure episode, and quality of life, 
      measured by the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), as well as 
      the adverse events (AEs).After treatment, GLSP can significant reduce the weekly 
      seizure frequency, compared with it before the treatment (P = .04). However, GLSP 
      did not exert promising effect in each seizure episode (P = .13), and quality of 
      life, measured by the QOLIE-31 scale (P = .11). Additionally, only minor AEs 
      occurred during the treatment period.The results of this study showed that GLSP 
      may be effective for reducing the weekly seizure frequency. Further studies are 
      still needed to warrant this result.
FAU - Wang, Guo-Hui
AU  - Wang GH
AD  - First Ward of Neurology Department, First Affiliated Hospital of Jiamusi 
      University, Jiamusi Second Ward of Neurology Department, Hongqi Affiliated 
      Hospital of Mudanjiang Medical University, Mudanjiang Department of Physiology, 
      Basic Medical College, Jiamusi University, Jiamusi, China.
FAU - Li, Xin
AU  - Li X
FAU - Cao, Wen-Hui
AU  - Cao WH
FAU - Li, Jing
AU  - Li J
FAU - Wang, Li-Hua
AU  - Wang LH
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Powders)
SB  - IM
MH  - Adult
MH  - Epilepsy/complications/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Powders/administration & dosage
MH  - Quality of Life
MH  - *Reishi
MH  - Retrospective Studies
MH  - Seizures/epidemiology/etiology
MH  - *Spores, Fungal
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5999473
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/06/08 06:00
MHDA- 2018/06/14 06:00
PMCR- 2018/06/18
CRDT- 2018/06/08 06:00
PHST- 2018/06/08 06:00 [entrez]
PHST- 2018/06/08 06:00 [pubmed]
PHST- 2018/06/14 06:00 [medline]
PHST- 2018/06/18 00:00 [pmc-release]
AID - 00005792-201806080-00029 [pii]
AID - MD-D-18-02314 [pii]
AID - 10.1097/MD.0000000000010941 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jun;97(23):e10941. doi: 10.1097/MD.0000000000010941.